← The Wire
VRTXNasdaq
VERTEX PHARMACEUTICALS INC / MA
Pharmaceutical Preparations · MA · CIK 875320
Discovers and develops small-molecule drugs and gene-editing therapies for serious diseases
red 8-K · 90d🔥 High media attention
$112.92B
Market cap
$499.65
Last close
+1.7%
1D
+7.0%
5D
2.1M
Volume
Price · last 39 sessions+16.2%
May 4L $424.36 · H $499.65Jun 29
92
Total filings
May 13, 2026
Last filing
12/31
Fiscal year end
DEFA14ADEFA14AApr 29, 2026DEFA14ADEFA14AApr 2, 2026DEFA14ADEFA14AApr 3, 2025DEFA14AVERTEX PHARMACEUTICALS INC - DEFA14AApr 4, 2024DEFA14AVERTEX PHARMACEUTICALS INC - DEFA14AApr 6, 2023DEFA14AVERTEX PHARMACEUTICALS INC - DEFA14AApr 7, 2022DEFA14AVERTEX PHARMACEUTICALS INC - DEFA14AApr 8, 2021
Insider Activity
In the 90 days to Mar 27, 2026: 12 sold $76.1M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 27, 2026 | Bozic CarmenEVP and CMO | Sell | 2,329 | $450.95 | $1.1M |
| Mar 13, 2026 | Bozic CarmenEVP and CMO | Sell | 2,329 | $481.79 | $1.1M |
| Mar 11, 2026 | Mckechnie DuncanEVP, Chief Commercial Officer | Sell | 2,633 | $498.42 | $1.3M |
| Mar 4, 2026 | Mckechnie DuncanEVP, Chief Commercial Officer | Sell | 2,437 | $475.30 | $1.2M |
| Mar 2, 2026 | Liu JoyEVP and Chief Legal Officer | Sell | 892 | $495.96 | $442K |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 15,580 | $495.38 | $7.7M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 5,995 | $496.16 | $3.0M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 3,498 | $494.33 | $1.7M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 3,278 | $488.27 | $1.6M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 2,725 | $490.54 | $1.3M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 2,520 | $493.29 | $1.2M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 2,510 | $487.13 | $1.2M |
| Feb 27, 2026 | Bozic CarmenEVP and CMO | Sell | 2,329 | $480.31 | $1.1M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 1,725 | $496.95 | $857K |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 949 | $491.30 | $466K |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 460 | $489.32 | $225K |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 400 | $479.75 | $192K |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 240 | $482.84 | $116K |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 120 | $481.50 | $58K |
| Feb 26, 2026 | Ambrose KristenSVP & Chief Accounting Officer | Sell | 357 | $483.36 | $173K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
🔥 High media attentionCoverage (30d): 12 reputable articles · skews ▲ positive.
MarketWatchVertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains3d agoMarketWatchVertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains4d agoMarketWatchVertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains7d agoMarketWatchVertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day11d agoMarketWatchVertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day12d agoMarketWatchVertex Pharmaceuticals Inc. stock rises Monday, still underperforms market14d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance